-
Something wrong with this record ?
Disease burden, clinical management and unmet treatment need of patients with moderate to severe atopic dermatitis; consensus statements, insights and practices from CERTADE (Central/Eastern EU, Russia, Turkiye AD Experts) Delphi panel
M. Trzeciak, L. Rudnicka, P. Arenberger, B. Engin, A. L'vov, S. Alper, E. Alpsoy, N. Benáková, S. Bobko, M. Borlu, M. Czarnecka-Operacz, O. Elisyutina, T. Ergun, I. Ertam, E. Fedenko, O. Filipovská, D. Fomina, A. Gadzhigoroeva, M. Kojanová, A....
Status not-indexed Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2014
Free Medical Journals
from 2014
PubMed Central
from 2014
Europe PubMed Central
from 2014
Open Access Digital Library
from 2014-01-01
Open Access Digital Library
from 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2014
- Publication type
- Journal Article MeSH
BACKGROUND: There is limited insight into the current disease burden and everyday clinical management of moderate-to- severe AD in Poland, Czechia, Russia, and Turkiye. Therefore, this study aimed to get information-driven insights regarding the current disease burden and clinical management of patients with moderate-to-severe AD with common and differentiating aspects of the patient journey and establish a consensus. METHODS: In this modified 2-round Delphi panel, 133 questions were asked in total to 27 dermatologists. A consensus was achieved when 70% of the panel members strongly agreed or agreed (or strongly disagreed or disagreed) with an item. Statements with <40% agreement dropped from the Delphi rounds and were not repeated. RESULTS: The results state that AD has a significant impact on the quality of life for both patients and their families with social and economic consequences in these countries. While there were significant dissimilarities regarding the current treatment approach by preference order and treatment duration among participants, there was also a high percentage of consensus on literature and guideline-based statements. Current topical therapies and the immune response modifiers were not found to be sufficient by panelists to cover the therapeutic needs of patients with moderate-to-severe AD. Moreover, panelists highlighted the significant burden of adverse events with the off-label use of currently available immunosuppressants. CONCLUSIONS: These results underlined that there is a significant disease burden with an unmet treatment need for patients with moderate-to-severe AD in Poland, Czechia, Russia, and Turkiye.
Department of Dermatology 1 M Sechenov Moscow Medical University Moscow Russia
Department of Dermatology AGEL Prague Czechia
Department of Dermatology and Venereology Akdeniz University Antalya Türkiye
Department of Dermatology and Venereology Erciyes University Kayseri Türkiye
Department of Dermatology and Venereology Koç University İstanbul Türkiye
Department of Dermatology Ege University İzmir Türkiye
Department of Dermatology Hospital in Ústí nad Labem Ústí nad Labem Czechia
Department of Dermatology Marmara University İstanbul Türkiye
Department of Dermatology Medical University of Poznań Poznań Poland
Department of Dermatology Medical University of Warsaw Warsaw Poland
Department of Dermatology Military Institute of Medicine Warsaw Poland
Department of Dermatology University of Rzeszow Rzeszów Poland
Department of Dermatology Venereology and Allergology Medical University of Gdańsk Gdańsk Poland
Department of Dermatovenereology 1st Medical Faculty Charles University Prague Czechia
Department of Dermatovenerology 3rd Faculty of Medicine Charles University of Prague Prague Czechia
Dermatology and Venereology Clinic Medical University Łodź Poland
Moscow Scientific and Practical Centre of Dermatovenereology and Cosmetology Moscow Russia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018345
- 003
- CZ-PrNML
- 005
- 20241016081909.0
- 007
- ta
- 008
- 241008e20240619sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fmed.2024.1402493 $2 doi
- 035 __
- $a (PubMed)38962737
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Trzeciak, Magdalena $u Department of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Gdańsk, Poland
- 245 10
- $a Disease burden, clinical management and unmet treatment need of patients with moderate to severe atopic dermatitis; consensus statements, insights and practices from CERTADE (Central/Eastern EU, Russia, Turkiye AD Experts) Delphi panel / $c M. Trzeciak, L. Rudnicka, P. Arenberger, B. Engin, A. L'vov, S. Alper, E. Alpsoy, N. Benáková, S. Bobko, M. Borlu, M. Czarnecka-Operacz, O. Elisyutina, T. Ergun, I. Ertam, E. Fedenko, O. Filipovská, D. Fomina, A. Gadzhigoroeva, M. Kojanová, A. Lesiak, A. Michenko, N. Murashkin, W. Owczarek, E. Özkaya, Z. Plzáková, A. Reich, M. Selerova, BA. Gurbuz
- 520 9_
- $a BACKGROUND: There is limited insight into the current disease burden and everyday clinical management of moderate-to- severe AD in Poland, Czechia, Russia, and Turkiye. Therefore, this study aimed to get information-driven insights regarding the current disease burden and clinical management of patients with moderate-to-severe AD with common and differentiating aspects of the patient journey and establish a consensus. METHODS: In this modified 2-round Delphi panel, 133 questions were asked in total to 27 dermatologists. A consensus was achieved when 70% of the panel members strongly agreed or agreed (or strongly disagreed or disagreed) with an item. Statements with <40% agreement dropped from the Delphi rounds and were not repeated. RESULTS: The results state that AD has a significant impact on the quality of life for both patients and their families with social and economic consequences in these countries. While there were significant dissimilarities regarding the current treatment approach by preference order and treatment duration among participants, there was also a high percentage of consensus on literature and guideline-based statements. Current topical therapies and the immune response modifiers were not found to be sufficient by panelists to cover the therapeutic needs of patients with moderate-to-severe AD. Moreover, panelists highlighted the significant burden of adverse events with the off-label use of currently available immunosuppressants. CONCLUSIONS: These results underlined that there is a significant disease burden with an unmet treatment need for patients with moderate-to-severe AD in Poland, Czechia, Russia, and Turkiye.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rudnicka, Lidia $u Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
- 700 1_
- $a Arenberger, Petr $u Department of Dermatovenerology, Third Faculty of Medicine, Charles University of Prague, Prague, Czechia
- 700 1_
- $a Engin, Burhan $u Department of Dermatology and Venerology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, İstanbul, Türkiye
- 700 1_
- $a L'vov, Andrey $u Department of Dermatology, Federal State Budgetary Institution of Continuing Professional Education "Central State Medical Academy", Moscow, Russia $u Department of Dermatology, Medical Research and Educational Center, Lomonosov Moscow State University, Moscow, Russia
- 700 1_
- $a Alper, Sibel $u Department of Dermatology and Venereology, Koç University, İstanbul, Türkiye
- 700 1_
- $a Alpsoy, Erkan $u Department of Dermatology and Venereology, Akdeniz University, Antalya, Türkiye
- 700 1_
- $a Benáková, Nina $u Department of Dermatovenereology, 1st Medical Faculty, Charles University, Prague, Czechia
- 700 1_
- $a Bobko, Svetlana $u Moscow Scientific and Practical Centre of Dermatovenereology and Cosmetology, Moscow, Russia
- 700 1_
- $a Borlu, Murat $u Department of Dermatology and Venereology, Erciyes University, Kayseri, Türkiye
- 700 1_
- $a Czarnecka-Operacz, Magdalena $u Department of Dermatology, Medical University of Poznań, Poznań, Poland
- 700 1_
- $a Elisyutina, Olga $u NRC Institute of Immunology FMBA of Russia, Moscow, Russia
- 700 1_
- $a Ergun, Tulin $u Department of Dermatology, Marmara University, İstanbul, Türkiye
- 700 1_
- $a Ertam, Ilgen $u Department of Dermatology, Ege University, İzmir, Türkiye
- 700 1_
- $a Fedenko, Elena $u NRC Institute of Immunology FMBA of Russia, Moscow, Russia
- 700 1_
- $a Filipovská, Olga $u Department of Dermatology, Hospital in Ústí nad Labem, Ústí nad Labem, Czechia
- 700 1_
- $a Fomina, Daria $u Centre of Allergy and Immunology, Clinical State Hospital 52, Moscow Ministry of Healthcare, Moscow, Russia $u Department of Dermatology, I. M. Sechenov Moscow Medical University, Moscow, Russia
- 700 1_
- $a Gadzhigoroeva, Aida $u Moscow Scientific and Practical Centre of Dermatovenereology and Cosmetology, Moscow, Russia
- 700 1_
- $a Kojanová, Martina $u Department of Dermatovenereology, 1st Medical Faculty, Charles University, Prague, Czechia
- 700 1_
- $a Lesiak, Aleksandra $u Dermatology and Venereology Clinic, Medical University, Łodź, Poland
- 700 1_
- $a Michenko, Anna $u Department of Dermatology, Federal State Budgetary Institution of Continuing Professional Education "Central State Medical Academy", Moscow, Russia $u Department of Dermatology, Medical Research and Educational Center, Lomonosov Moscow State University, Moscow, Russia
- 700 1_
- $a Murashkin, Nikolay $u Department of Dermatology, Federal State Autonomous Institution, Scientific Centre of Children's Health of the Ministry of Health of the Russian Federation, Moscow, Russia
- 700 1_
- $a Owczarek, Witold $u Department of Dermatology, Military Institute of Medicine, Warsaw, Poland
- 700 1_
- $a Özkaya, Esen $u Istanbul Faculty of Medicine, Department of Dermatology and Venereology, Istanbul University, İstanbul, Türkiye
- 700 1_
- $a Plzáková, Zuzana $u Department of Dermatovenereology, 1st Medical Faculty, Charles University, Prague, Czechia
- 700 1_
- $a Reich, Adam $u Department of Dermatology, University of Rzeszow, Rzeszów, Poland
- 700 1_
- $a Selerova, Marie $u Department of Dermatology, AGEL, Prague, Czechia
- 700 1_
- $a Gurbuz, Burcu A $u Pfizer, İstanbul, Türkiye
- 773 0_
- $w MED00188756 $t Frontiers in medicine $x 2296-858X $g Roč. 11 (20240619), s. 1402493
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38962737 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241008 $b ABA008
- 991 __
- $a 20241016081904 $b ABA008
- 999 __
- $a ok $b bmc $g 2196530 $s 1230298
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 11 $c - $d 1402493 $e 20240619 $i 2296-858X $m Frontiers in medicine $n Front Med (Lausanne) $x MED00188756
- LZP __
- $a Pubmed-20241008
